Fibroblast Growth Factor 19 (FGF19)

Class endocrine fibroblast growth factor / metabolic growth factorReceptor FGFR4 with beta-Klotho co-receptor

Function

Fibroblast growth factor 19 is an endocrine peptide hormone involved in bile acid regulation, hepatic metabolism, glucose signaling, energy balance, and gastrointestinal-liver communication. FGF19 functions as an intestinally derived endocrine signal that coordinates nutrient-related communication between the digestive tract and liver metabolism.

The hormone contributes to regulation of bile acid synthesis, glycogen metabolism, lipid signaling, energy utilization, and hepatic nutrient adaptation. FGF19 also participates in communication pathways involving gallbladder physiology, intestinal nutrient sensing, and metabolic endocrine regulation. Through these actions, it supports coordinated digestive and hepatic metabolic homeostasis.

Production

FGF19 is produced primarily by enteroendocrine cells within the ileum of the small intestine. Production increases after food intake when bile acids activate intestinal farnesoid X receptor signaling pathways that stimulate FGF19 synthesis.

After secretion, the hormone enters circulation and travels to the liver where it regulates bile acid metabolism and additional metabolic signaling pathways. Intestinal production therefore provides an endocrine feedback mechanism linking digestion with hepatic physiology.

Regulation

FGF19 production is regulated mainly by bile acid signaling, nutrient intake, intestinal receptor activation, metabolic status, and enterohepatic communication pathways. Farnesoid X receptor activation is a major driver of synthesis following meals.

The hormone acts through fibroblast growth factor receptor systems together with beta-Klotho co-receptors expressed primarily in liver tissue. Receptor activation influences bile acid synthesis enzymes, glycogen pathways, lipid metabolism, and energy-related signaling systems. Through these integrated gastrointestinal-hepatic endocrine pathways, FGF19 coordinates bile acid homeostasis, nutrient-responsive signaling, liver metabolism, and metabolic adaptation.

Identity & Secretion

Primary Source GlandIleal enterocytes, intestinal epithelial cells

Secretion PatternEndocrine intestinal-liver signaling

Half-life30 min

PrecursorFGF19 protein precursor

Nutrient Requirements

Nutrient Precursors

amino acids, protein synthesis substrates

Required Vitamins

vitamin-b6,vitamin-b9,vitamin-c

Required Minerals

zinc,magnesium,selenium,phosphorus

Key Foods

broccoli,kale,spinach,garlic,blueberry,pomegranate,green-tea-brewed,turmeric-ground,oats-cooked,brown-rice-cooked

Targets & Signaling

Target Tissues

Liver, bile acid metabolism tissues, intestine, gallbladder, hepatobiliary tissues, gastrointestinal tumor microenvironment

Feedback Loops

FGF19 signaling activates FGFR4/beta-Klotho pathways including MAPK/ERK, PI3K/AKT, STAT3, bile acid feedback regulation, CYP7A1 suppression, and metabolic feedback between intestine and liver.

Second Messengers

FGFR4,beta-Klotho,MAPK,ERK,PI3K,AKT,STAT3,FXR,CYP7A1

Pathways Involved

fgfr-signaling,mapk-erk-pathway,pi3k-akt-pathway,bile-acid-synthesis,insulin-signaling,nfkb-pathway,mtorc1-signaling,cell-cycle-control

Key Functions

Bile acid feedback regulation, liver metabolic signaling, glucose and lipid metabolism, hepatobiliary growth signaling, intestinal-liver communication, proliferation signaling.

Plant-Based Focus

Whole-food plant-based patterns rich in legumes, whole grains, cruciferous vegetables, berries, leafy greens, mushrooms, and high-fiber foods support gut-liver metabolic balance and provide phytochemicals studied for modulation of bile acid signaling, inflammation, oxidative stress, MAPK/ERK, PI3K/AKT, and liver metabolic pathways.

Clinical Context

Normal RangeContext dependent; circulating levels vary with bile acid signaling, meal timing, and metabolic state

Unitspg/mL

Assay Notes
FGF19 is evaluated mostly in metabolic, liver, bile acid, obesity, diabetes, and hepatobiliary cancer research rather than routine clinical hormone testing.

Linked Knowledge

Phytochemicals

quercetin,egcg,curcumin,sulforaphane,resveratrol,chlorogenic-acid,apigenin,luteolin

Amino Acids

glutamine,glycine,arginine,cysteine,serine

Foods

broccoli,kale,spinach,garlic,blueberry,pomegranate,green-tea-brewed,turmeric-ground,oats-cooked,brown-rice-cooked

Vitamins

vitamin-b6,vitamin-b9,vitamin-c,vitamin-e

Minerals

magnesium,zinc,selenium,phosphorus,manganese

Cancers (context)

Liver Cancer,Cholangiocarcinoma,Gastric Cancer,Colorectal Cancer,Pancreatic Cancer,Gallbladder Cancer

Ailments

NAFLD,Insulin Resistance,Metabolic Syndrome,Type 2 Diabetes,Gallbladder Sluggishness,Gallstone Formation,Chronic Inflammation

Dietary Modulators

Legumes, whole grains, cruciferous vegetables, berries, mushrooms, leafy greens, green tea, turmeric, and high-fiber plant foods

Inhibitors / Activators

Inhibitors

quercetin,egcg,curcumin,sulforaphane,resveratrol,luteolin

Activators

Bile acid activation, FXR signaling, intestinal-liver feedback, metabolic stress, fatty liver signaling, inflammatory cytokines

Summary

FGF19 is an intestinal-liver endocrine growth factor that regulates bile acid feedback and liver metabolism. In cancer biology, excessive FGF19/FGFR4 signaling is especially important in liver and gastrointestinal cancers because it can support proliferation, survival signaling, and hepatobiliary tumor progression.

SUMMARY OF EFFECTS ON THE BODY

FGF19 supports normal bile acid feedback and gut-liver metabolic communication, while dysregulated FGF19/FGFR4 signaling is linked with abnormal proliferation, liver metabolic stress, bile acid pathway disruption, and hepatobiliary tumor biology.

Research

FGF19 is an endocrine fibroblast growth factor produced mainly by ileal enterocytes after FXR activation. It signals through FGFR4 and beta-Klotho to regulate bile acid synthesis, especially CYP7A1 suppression, and liver metabolic feedback. In oncology research, the FGF19/FGFR4 axis is strongly connected to hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, colorectal cancer, and gastrointestinal tumor progression.